Keros Therapeutics Inc (KROS)
49.36
-0.14
(-0.28%)
USD |
NASDAQ |
Jun 14, 16:00
49.32
-0.04
(-0.08%)
After-Hours: 20:00
Keros Therapeutics Cash from Investing (Quarterly): -0.946M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.946M |
| December 31, 2023 | -0.541M |
| September 30, 2023 | -0.55M |
| June 30, 2023 | -0.311M |
| March 31, 2023 | -1.062M |
| December 31, 2022 | -0.351M |
| September 30, 2022 | -0.176M |
| June 30, 2022 | -0.567M |
| March 31, 2022 | -0.147M |
| December 31, 2021 | -0.159M |
| September 30, 2021 | -0.145M |
| Date | Value |
|---|---|
| June 30, 2021 | -0.51M |
| March 31, 2021 | -0.21M |
| December 31, 2020 | -0.06M |
| September 30, 2020 | -0.03M |
| June 30, 2020 | -0.028M |
| March 31, 2020 | -0.176M |
| December 31, 2019 | -0.018M |
| September 30, 2019 | -0.082M |
| June 30, 2019 | -0.171M |
| March 31, 2019 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-1.062M
Minimum
Mar 2023
-0.018M
Maximum
Dec 2019
-0.312M
Average
-0.176M
Median
Mar 2020
Cash from Investing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | -67.62M |
| Biomarin Pharmaceutical Inc | -14.24M |
| Sarepta Therapeutics Inc | 218.80M |
| PTC Therapeutics Inc | -114.93M |
| ADMA Biologics Inc | -2.362M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -44.56M |
| Cash from Financing (Quarterly) | 156.80M |
| Free Cash Flow | -137.18M |
| Free Cash Flow Per Share (Quarterly) | -1.275 |
| Free Cash Flow to Equity (Quarterly) | -45.51M |
| Free Cash Flow Yield | -8.89% |